难治性口腔扁平苔藓的免疫替代药物及作用机制研究进展

doi:10.13701/j.cnki.kqyxyj.2025.01.002

摘要/Abstract

摘要： 口腔扁平苔藓(oral lichen planus, OLP)是一种常见的口腔黏膜慢性炎性疾病,其发病机制主要涉及T细胞介导的抗原特异性免疫和非特异性免疫,糖皮质激素是国际公认的一线药物。对糖皮质激素抵抗或反应差的难治性OLP是临床管理的一大难点。由于局部免疫紊乱在难治性OLP的发生发展过程中发挥重要作用,因此探索有效且安全的免疫替代治疗药物成为近年研究热点。本文基于OLP的免疫发病机制,对常用免疫替代药物的临床应用和作用机制进行总结,并对潜在免疫替代药物作用靶点进行展望,旨在为难治性OLP的临床管理和未来研究提供参考。

关键词: 口腔扁平苔藓, 难治性, 免疫发病机制, 免疫替代治疗药物, 药物作用机制

Abstract: Oral lichen planus(OLP)is a common chronic inflammatory disease of the oral mucosa, with its pathogenesis primarily involving T-cell-mediated antigen-specific immunity and non-specific immunity, and glucocorticoids are internationally recognized as first-line drugs. Refractory OLP,which is resistant or poorly responsive to glucocorticoids, is a major difficulty in clinical management. Given the significant role of local immune disorders in the development of refractory OLP, exploring effective and safe immune-replacement drugs has become a hot research topic in recent years. This review summarizes the clinical applications and mechanisms of action of commonly used immune-replacement agents based on the immunopathogenesis of oral lichen planus, which offers insights into potential target of immune-replacement agents, aiming to provide a reference for the clinical management and future research of refractory OLP.

Key words: oral lichen planus, refractory, immunopathogenesis, immune-replacement drugs, mechanisms of drug action

余霜, 周红梅. 难治性口腔扁平苔藓的免疫替代药物及作用机制研究进展[J]. 口腔医学研究, 2025, 41(1): 7-11.

YU Shuang, ZHOU Hongmei. Progress on Immune-replacement Drugs and Mechanisms of Action in Refractory Oral Lichen Planus[J]. Journal of Oral Science Research, 2025, 41(1): 7-11.

参考文献

[1] 中华口腔医学会口腔黏膜病学专业委员会,中华口腔医学会中西医结合专业委员会.口腔扁平苔藓诊疗指南(修订版)[J].中华口腔医学杂志,2022,57(2): 115-120.
[2] Louisy A, Humbert E, Samimi M. Oral lichen planus: an update on diagnosis and management [J]. Am J Clin Dermatol, 2023, 25(1):35-53.
[3] Ioannides D, Vakirlis E, Kemeny L, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology [J]. J Eur Acad Dermatol Venereol, 2020, 34(7): 1403-1414.
[4] Solimani F, Forchhammer S, Schloegl A, et al. Lichen planusa clinical guide [J]. J Dtsch Dermatol Ges, 2021, 19(6): 864-882.
[5] Mu J, Zeng Q, Wu F, et al. Refractory oral lichen planus: a definition employing statistical analysis [J]. Oral Dis, 2022, 28(8): 2172-2174.
[6] Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(1): 72-80.
[7] El-Howati A, Thornhill MH, Colley HE, et al. Immune mechanisms in oral lichen planus [J]. Oral Dis, 2023, 29(4): 1400-1415.
[8] Deng S, Xu Y, Wang X, et al. Study on the role of salivary flora and NF-κB inflammatory signal pathway in oral lichen planus [J]. Inflammation, 2020, 43(3): 994-1008.
[9] Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology [J]. Nat Rev Rheumatol, 2020, 16(3): 155-166.
[10] Rivas-Tolosa N, Requena C, Llombart B, et al. Antimalarial drugs for the treatment of oral erosive lichen planus [J]. Dermatology, 2016, 232(1): 86-90.
[11] Gisondi P, Piaserico S, Bordin C, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events [J]. Clin Exp Rheumatol, 2021, 39(5): 1099-1107.
[12] Cho O, Takada S, Odaka T, et al. Tacrolimus (FK506) exhibits fungicidal effects against Candida parapsilosis sensu stricto via inducing apoptosis [J]. J Fungi (Basel), 2023, 9(7): 778.
[13] Broen JCA, Van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology [J]. Nat Rev Rheumatol, 2020, 16(3): 167-178.
[14] Resende J, Chaves V, Aarestrup F, et al. Oral lichen planus treated with tacrolimus 0.1% [J]. Int J Clin Exp Med, 2013, 6(10): 917-921.
[15] Ribero S, Stieger M, Quaglino P, et al. Efficacy of topical tacrolimus for oral lichen planus: real-life experience in a retrospective cohort of patients with a review of the literature [J]. J Eur Acad Dermatol Venereol, 2015, 29(6): 1107-1113.
[16] Arduino PG, Carbone M, Della Ferrera F, et al. Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study [J]. J Eur Acad Dermatol Venereol, 2014, 28(4): 475-482.
[17] Kiyani A, Sohail K, Saeed MHB. Efficacy of 0.1% tacrolimus in long-term management of erosive lichen planus [J]. J Dermatol Treat, 2021, 32(3): 367-371.
[18] Voûte AB, Schulten EA, Langendijk PN, et al. Cyclosporin A in an adhesive base for treatment of recalcitrant oral lichen planus. an open trial [J]. Oral Surg Oral Med Oral Pathol, 1994, 78(4): 437-441.
[19] Itin P, Surber C, Büchner S. Lack of effect after local treatment with a new ciclosporin formulation in recalcitrant erosive oral lichen planus [J]. Dermatology, 1992, 185(4): 262-265.
[20] Demitsu T, Sato T, Inoue T, et al. Corticosteroid-resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy [J]. Int J Dermatol, 2000, 39(1): 79-80.
[21] Gupta A, Sardana K, Gautam RK. Looking beyond the cyclosporine "swish and spit" technique in a recalcitrant case of erosive lichen planus involving the tongue [J]. Case Rep Dermatol, 2017, 9(3): 177-183.
[22] Dalmau J, Puig L, Roe E, et al. Successful treatment of oral erosive lichen planus with mycophenolate mofetil [J]. J Eur Acad Dermatol Venereol, 2007, 21(2): 259-260.
[23] Wee JS, Shirlaw PJ, Challacombe SJ, et al. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients [J]. Br J Dermatol, 2012, 167(1): 36-43.
[24] Afzali S, Mohammadisoleimani E, Mansoori Y, et al. The potential roles of Th17 cells in the pathogenesis of oral lichen planus [J]. Inflamm Res, 2023, 72(7): 1513-1524.
[25] Piccinni M, Lombardelli L, Logiodice F, et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus [J]. Oral Dis, 2014, 20(2): 212-218.
[26] Wang Y, Zhou J, Fu S, et al. A study of association between oral lichen planus and immune balance of Th1/Th2 cells [J]. Inflammation, 2015, 38(5): 1874-1879.
[27] Wei W, Sun Q, Deng Y, et al. Mixed and inhomogeneous expression profile of Th1/Th2 related cytokines detected by cytometric bead array in the saliva of patients with oral lichen planus [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(2): 142-151.
[28] Xiong C, Li Q, Lin M, et al. The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial [J]. J Oral Pathol Med, 2009, 38(7): 551-558.
[29] Metwalli M, Marei A, Toama M, et al. Bacillus Calmette-Guérin polysaccharide nucleic acid extract versus triamcinolone acetonide intralesional injection in the treatment of oral lichen planus: a comparative study [J]. Egypt J DermatolVenerol, 2018, 38(1): 1-11.
[30] Piñas L, Alkhraisat MH, Fernández RS, et al. Biological therapy of refractory ulcerative oral lichen planus with plasma rich in growth factors [J]. Am J Clin Dermatol, 2017, 18(3): 429-433.
[31] Khattab FM, Ghonaim R, Samir MA. Estimation of neutrophil activation marker in lichen planus patients [J]. J Cosmet Dermatol, 2022, 21(4): 1625-1628.
[32] Merigo E, Oppici A, Parlatore A, et al. Platelet-rich plasma (PRP) rinses for the treatment of non-responding oral lichen planus: A case report [J]. Biomedicines, 2018, 6(1): 15.
[33] Pinas L, Alkhraisat MH, Suarez-Fernandez R, et al. Biomolecules in the treatment of lichen planus refractory to corticosteroid therapy: clinical and histopathological assessment [J]. Ann Anat, 2018, 216: 159-163.
[34] Anitua E, Eguia A, Alkhraisat MH, et al. Oral lichen planus treated with plasma rich in growth factors [J]. Cutis, 2022, 109(3):163-166.
[35] Khalil A, Nemer G. Thalidomide-revisited: Are COVID-19 patients going to be the latest victims of yet another theoretical drug-repurposing? [J]. Front Immunol, 2020, 11:1248.
[36] Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide [J]. Arch Dermatol, 2000, 136(12):1442-1443.
[37] Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology [J]. Clin Exp Dermatol, 2022, 47(4): 667-674.
[38] Sadeghi M, Dehnavi S, Jamialahmadi T, et al. Neutrophil extracellular trap: a key player in the pathogenesis of autoimmune diseases [J]. Int Immunopharmacol, 2023, 116: 109843.
[39] Jablonska E, Garley M, Surazynski A, et al. Neutrophil extracellular traps (NETs) formation induced by TGF-β in oral lichen planus-possible implications for the development of oral cancer [J]. Immunobiology, 2020, 225(2): 151901.